Webinar Outline:

• Understand the clinical evolution and expanding indications of GLP-1 therapies

• Review preclinical evidence for novel GLP-1 combinations (e.g., with Bimagrumab or MGL-3196)

• Explore key mouse models for obesity and its comorbidities, including MASH and cardiovascular disease

• Examine a case study using mouse models to evaluate GLP-1-receptor-targeted therapies

For more information, please contact sales@gempharmatech.com